TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 316 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2019. The put-call ratio across all filers is 1.05 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,045,633 | -89.0% | 67,591 | -88.8% | 0.02% | -88.7% |
| Q2 2023 | $9,481,377 | +1982.0% | 603,525 | +2084.1% | 0.20% | +2166.7% |
| Q1 2023 | $455,391 | -39.3% | 27,633 | -52.2% | 0.01% | -62.5% |
| Q3 2022 | $750,000 | -77.3% | 57,838 | -75.4% | 0.02% | -74.2% |
| Q2 2022 | $3,306,000 | +122.8% | 235,454 | +189.7% | 0.09% | +12.0% |
| Q1 2021 | $1,484,000 | -51.0% | 81,274 | -52.1% | 0.08% | -65.3% |
| Q3 2020 | $3,028,000 | +87.4% | 169,748 | +88.4% | 0.24% | +106.0% |
| Q2 2020 | $1,616,000 | +18.1% | 90,117 | +0.0% | 0.12% | 0.0% |
| Q1 2020 | $1,368,000 | -37.0% | 90,110 | -18.2% | 0.12% | -30.5% |
| Q4 2019 | $2,172,000 | -11.5% | 110,103 | -22.9% | 0.17% | -45.4% |
| Q3 2019 | $2,455,000 | -0.4% | 142,759 | +2.5% | 0.31% | -1.3% |
| Q2 2019 | $2,465,000 | -59.1% | 139,269 | -52.9% | 0.31% | -69.2% |
| Q1 2019 | $6,024,000 | – | 295,733 | – | 1.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Glenview Capital Management | 16,104,222 | $294,063,000 | 4.98% |
| GMT CAPITAL CORP | 2,468,695 | $45,078,000 | 3.31% |
| MANAGED ASSET PORTFOLIOS, LLC | 1,065,756 | $19,461,000 | 3.13% |
| Blackcrane Capital, LLC | 14,571 | $1,723,000 | 2.72% |
| BFAM Partners (Cayman) Ltd | 328,690 | $6,002,000 | 2.36% |
| Paulson & Co. | 4,727,415 | $86,323,000 | 1.98% |
| Mondrian Investment Partners LTD | 3,510,404 | $59,677,000 | 1.28% |
| Lumbard & Kellner, LLC | 135,550 | $2,264,000 | 0.80% |
| DAVIDSON INVESTMENT ADVISORS | 500,203 | $9,134,000 | 0.78% |
| TFG Asset Management GP Ltd | 589,390 | $10,762,000 | 0.77% |